Moxaverine
Chemical compound
- A03AD30 (WHO)
- 1-Benzyl-3-ethyl-6,7-dimethoxyisoquinoline
- 10539-19-2
Y
- 70882
- 64045
N
- P3P08Y1XJ4
- D07089 Y
- DTXSID6057613
- Interactive image
- CCC1=NC(=C2C=C(C(=CC2=C1)OC)OC)CC3=CC=CC=C3
InChI
- InChI=1S/C20H21NO2/c1-4-16-11-15-12-19(22-2)20(23-3)13-17(15)18(21-16)10-14-8-6-5-7-9-14/h5-9,11-13H,4,10H2,1-3H3N
- Key:MYCMTMIGRXJNSO-UHFFFAOYSA-NN
N
Y (what is this?) (verify)Moxaverine has been used in therapy based on the direct vasodilatory effect of the drug, a phosphodiesterase inhibitor,[1] and on its influence on the rheological properties of red blood cells.[2]
Moxaverine hydrochloride (Kollateral forte®, Ursapharm. Saarbrücken, Germany) has been shown to increase ocular blood flow in patients with age-related macular degeneration, primary open angle glaucoma, and to increase choroidal and retrobulbar blood flow in elderly patients with eye diseases associated with hypo-perfusion.[3] The ocular efficacy of moxaverine has been explored in the clinic.[4]
References
- ^ Mannhold R (December 1988). "Inhibition of calmodulin dependent c-AMP-phosphodiesterase by moxaverine and papaverine". Arzneimittel-Forschung. 38 (12): 1806–8. PMID 2854468.
- ^ Schmid-Schönbein H, Schröder S, Grebe R, Artmann G, Eschweiler H, Teitel P (May 1988). "Influence of moxaverine hydrochloride on membrane curvature and microsieve filterability of red cells after exposure to hyperosmolarity and lactacidosis". Arzneimittel-Forschung. 38 (5): 710–6. PMID 3415714.
- ^ Pemp B, Garhofer G, Lasta M, Schmidl D, Wolzt M, Schmetterer L (March 2012). "The effects of moxaverine on ocular blood flow in patients with age-related macular degeneration or primary open angle glaucoma and in healthy control subjects". Acta Ophthalmologica. 90 (2): 139–45. doi:10.1111/j.1755-3768.2010.01878.x. PMID 20456253. S2CID 3269602.
- ^ Clinical trial number NCT01629680 for "A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects" at ClinicalTrials.gov
- v
- t
- e
Drugs for functional gastrointestinal disorders (A03)
functional
bowel
disorders
| Antimuscarinics |
| ||||
|---|---|---|---|---|---|
| Phosphodiesterase inhibitors |
| ||||
| Acting on serotonin receptors |
| ||||
| Other |
and derivatives
(antimuscarinics)
- Tertiary amines: Atropine
- Hyoscyamine
- Quaternary ammonium compounds:
- Methylatropine
- Fentonium bromide
- Cimetropium bromide
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
